08764600 · Active · incorporated 12 years, 10 months ago · Weybridge
Biotech Biotech & Life Sciences Drug Discovery Series B+
Antev is a clinical-stage biotech company developing Teverelix, a next-generation GnRH antagonist, for high cardiovascular risk prostate cancer patients.
Antev Limited is a private limited company registered at Companies House under number 08764600, incorporated on 6 November 2013, with a registered office in Weybridge. Its current status on the register is active. Its filed nature of business is research and experimental development on biotechnology (SIC 72110). Sonde has indexed 99 filings for this company, including 8 funding rounds. Its most recent round closed in August 2025, raising £878k.
| Round | Closed | Raised | Price per share |
|---|---|---|---|
| Round 8 | Aug 2025 | £878k | £2.47 |
| Round 7 | Jul 2025 | £282k | £15.00 |
| Round 6 | Nov 2023 | £101k | £15.00 |
| Round 5 | Jun 2022 | £4.8m | £15.00 |
| Round 4 | Nov 2020 | £1.3m | £15.00 |
| Round 3 | Jun 2019 | £3.8m | £12.06 |
Showing the 6 most recent of 8 rounds.
Showing the 13 most recent of 99 filings.
See the complete cap table with every shareholder, founder tags, dilution across 44 share allotments, round-by-round fundraising history, and the full filing timeline — parsed from official Companies House documents.
Create a free account Sign inFree accounts open 3 companies in full detail — no card required.